Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Running, not enrolling · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8

In brief

This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.

Key facts

Study ID
NCT04137107
Run by
Alliance for Clinical Trials in Oncology
People needed
220
Starts
2020-06-17
Expected to finish
2026-12-31
Last updated by the study team
2026-01-26

Who can join

Age: 25 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.